in

COVID-19 : Johnson & Johnson requests emergency vaccine authorization from WHO

What you should know about the Johnson & Johnson vaccine 0:56

. – Johnson & Johnson announced this Friday that it has requested an emergency use listing for its single-dose COVID-19 vaccine from the World Health Organization.

The company said it had submitted its late-stage trial data to WHO.

An emergency use classification would make the vaccine available in more than 190 countries, including several developing countries.

If authorized, it would also allow Johnson & Johnson to supply the Covax program vaccines, for the global distribution and procurement of covid-19 vaccines for 190 participating countries.

The importance of the effectiveness of the Johnson & Johnson vaccine 1:02

In December, Johnson & Johnson reached an agreement with Gavi, the Vaccine Alliance, which supports the Covax program. If authorized, Johnson & Johnson expects to provide up to 500 million doses to the initiative through next year, the company said.

“Our presentation to the World Health Organization marks another important step in our effort to combat COVID-19 and also in our unwavering commitment to equitable access,” said Dr. Paul Stoffels, Vice Chairman of the Executive Committee of Johnson & Johnson and scientific director, in a statement.

“If we want to end the global pandemic, life-saving innovations, such as vaccines, must be available to all countries,” he added.

J&J submitted an application for a conditional marketing authorization in the European Union on Monday. Next Friday, an independent committee of the US Food and Drug Administration (FDA) will consider the data the company submitted for an emergency use authorization of the vaccine in the United States.

The efficacy of the COVID-19 vaccine against moderate and severe diseases varied from country to country: 72% in the US; 66%, in Latin America, and 57%, in South Africa. It was 66% effective worldwide, a measurement made one month after its application.

Johnson & Johnson’s vaccine is 85% overall effective in preventing hospitalization and 100% in preventing death in all regions where it was tested.